title: The effectiveness of RECIST on survival in patients with NSCLC receiving chemotherapy with or without target agents as first-line treatment.
abstract: We analyzed the correlation between survival and antitumor effect evaluated by RECIST in advanced NSCLC patients with chemotherapy plus target therapy or not as first-line treatment, to examine the applicability of RECIST in this population. The patients were screened from 4 clinical trials (12621, 12006, FASTACT-I, and FASTACT-II), and those who received chemotherapy plus target therapy or chemotherapy alone were eligible. Among the 59 enrolled patients, 29 received combination therapy, while the other 30 received chemotherapy only. In the combination therapy group, patients with PR or SD had longer overall survival (OS) than those with PD (P < 0.001 and P = 0.002, respectively). However, in the chemotherapy alone group, compared with PD patients, either PR or SD group had no significant overall survival benefit (P = 0.690 and P = 0.528, respectively). In summary, for advanced NSCLC patients receiving chemotherapy plus target therapy as first-line treatment and evaluated by RECIST criteria, SD has the same overall survival benefit as PR, suggesting that antitumor effective evaluation by RECIST criteria cannot be translated to overall survival benefit especially for this kind of patients. Therefore, developing a more comprehensive evaluation method to perfect RECIST criteria is thus warranted for patients received target therapy in NSCLC.
authors.affiliation: 1] Sun-Yat Sen University Cancer Center, Guangzhou, China [2] State Key Laboratory of Oncology in South China, Guangzhou 510060, China [3] Collaborative innovation Center for Cancer Medicine, Guangzhou 510060, China.
authors.forename: Ting
authors.initials: T
authors.lastname: Zhou
authors.affiliation: 1] Sun-Yat Sen University Cancer Center, Guangzhou, China [2] State Key Laboratory of Oncology in South China, Guangzhou 510060, China [3] Collaborative innovation Center for Cancer Medicine, Guangzhou 510060, China.
authors.forename: Lie
authors.initials: L
authors.lastname: Zheng
authors.affiliation: 1] Sun-Yat Sen University Cancer Center, Guangzhou, China [2] State Key Laboratory of Oncology in South China, Guangzhou 510060, China [3] Collaborative innovation Center for Cancer Medicine, Guangzhou 510060, China.
authors.forename: Zhihuang
authors.initials: Z
authors.lastname: Hu
authors.affiliation: 1] Sun-Yat Sen University Cancer Center, Guangzhou, China [2] State Key Laboratory of Oncology in South China, Guangzhou 510060, China [3] Collaborative innovation Center for Cancer Medicine, Guangzhou 510060, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: 1] Sun-Yat Sen University Cancer Center, Guangzhou, China [2] State Key Laboratory of Oncology in South China, Guangzhou 510060, China [3] Collaborative innovation Center for Cancer Medicine, Guangzhou 510060, China.
authors.forename: Wenfeng
authors.initials: W
authors.lastname: Fang
authors.affiliation: 1] Sun-Yat Sen University Cancer Center, Guangzhou, China [2] State Key Laboratory of Oncology in South China, Guangzhou 510060, China [3] Collaborative innovation Center for Cancer Medicine, Guangzhou 510060, China.
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Zhao
authors.affiliation: 1] Sun-Yat Sen University Cancer Center, Guangzhou, China [2] State Key Laboratory of Oncology in South China, Guangzhou 510060, China [3] Collaborative innovation Center for Cancer Medicine, Guangzhou 510060, China.
authors.forename: Jieying
authors.initials: J
authors.lastname: Ge
authors.affiliation: 1] Sun-Yat Sen University Cancer Center, Guangzhou, China [2] State Key Laboratory of Oncology in South China, Guangzhou 510060, China [3] Collaborative innovation Center for Cancer Medicine, Guangzhou 510060, China.
authors.forename: Hongyun
authors.initials: H
authors.lastname: Zhao
authors.affiliation: 1] Sun-Yat Sen University Cancer Center, Guangzhou, China [2] State Key Laboratory of Oncology in South China, Guangzhou 510060, China [3] Collaborative innovation Center for Cancer Medicine, Guangzhou 510060, China.
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012074:Remission Induction; D066066:Response Evaluation Criteria in Solid Tumors; D015996:Survival Rate; D014057:Tomography, X-Ray Computed